Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Matthew K WyniaLaurel E BeatyTellen D BennettNichole E CarlsonChristopher B DavisBethany M KwanDavid A MayerToan C OngSeth RussellJeffrey SteeleHeather R StockerAdane F WoguRichard D ZaneRonald J SokolAdit A GindePublished in: medRxiv : the preprint server for health sciences (2022)
Real-world evidence demonstrated mAb effectiveness in reducing hospitalization among COVID-19 outpatients, including during the Delta variant phase, and conferred an overall 89% reduction in 28-day mortality. Early outpatient treatment with mAbs should be prioritized, especially for individuals with highest risk for hospitalization.